Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dako Receives FDA Approval for Fast, Accurate, Nontoxic FISH Assay for Cancer Diagnostics

Published: Monday, February 18, 2013
Last Updated: Monday, February 18, 2013
Bookmark and Share
Dako, an Agilent Technologies Company, has introduced IQISH technology in the United States.

The technology will reduce the turnaround time for cancer evaluation from two days to three and a half hours. This will ease the waiting time and associated anxiety for the patient and allow physicians to more quickly initiate targeted cancer treatments.

HER2 IQFISH pharmDx, a fluorescence in situ hybridization (FISH) assay, is the first product approved by the U.S. Food and Drug Administration that uses the Dako IQISH technology, which is based on Dako's fast IQISH hybridization buffer chemistry.

“Every second counts when waiting for test results that will indicate how to treat your cancer most effectively,” said Lars Holmkvist, CEO of Dako and senior vice president, Agilent. “Dako is extremely proud to get the FDA’s approval to introduce this offering to our U.S. customers.”
IQISH stands for “instant quality in situ hybridization,” indicating the significantly reduced turnaround time of patients’ samples, without compromising the quality of the result.

“HER2 IQFISH pharmDx improves the workflow in the pathology laboratory and is a valuable aid in assessing patients for whom trastuzumab treatment is being considered,” said Dr. David Hardisson, University Hospital La Paz, School of Medicine, Autonomous University of Madrid, IdiPAZ, Madrid, Spain.

The HER2 IQFISH pharmDx assay can support laboratories in identifying HER2 gene status with great accuracy—and now, speed.

The HER2 gene encodes a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cells. In about one of every five breast cancers, the cancer cells make an excess of HER2 due to a HER2 gene mutation (amplification).

HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. As they are also less responsive to hormone treatment, medical treatments that specifically target HER2, for example trastuzumab, are often considered.

“The new protocol yields very distinct signals,” said Professor Giuseppe Viale, medical director at Istituto Europeo di Oncologia, Milano, Italy. “With a protocol duration of only three and a half hours, it will be much easier to plan laboratory time and handle urgent cases.”

“HER2 IQFISH pharmDx will provide more timely results, allowing us to incorporate FISH analysis into our routine workflow as easily as immunohistochemistry,” said Kenneth J. Bloom, MD, FCAP, chief medical officer, Clarient Diagnostic Services Inc., a GE Healthcare company, California, United States.

IQFISH is also nontoxic, as it replaces a hazardous formamide buffer with a safer ethylene carbonate, contributing to a healthier work environment in the pathology lab.

HER2 IQFISH pharmDx has been sold in Europe and countries working with CE labeling, the mark of compliance with relevant European regulations, since February 2012. HER2 IQFISH pharmDx is now available in the U.S.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent, Eurofins Genomics Collaborate
Agilent plans to offer custom components and an assembled plasmid service for Agilent’s SureVector next-generation cloning kits through a collaboration with Eurofins.
Monday, March 14, 2016
Best Practices for Breast Cancer Diagnosis
Agilent has published “Breast Cancer Diagnosis: Past, Present and Future,” a white paper on the use of immunohistochemistry in diagnosing and treating breast cancer.
Monday, March 14, 2016
Agilent Invests $80M in Lasergen
Company has announced that it has invested $80 million in Lasergen, with innovative next-generation sequencing technology for clinical applications.
Friday, March 11, 2016
Agilent Technologies Announces Early Access to Custom guideRNA for Functional Genomics
Company has announced a program that gives biologists conducting functional genomics research early access to a potential new resource.
Saturday, February 13, 2016
Agilent Technologies and 10x Genomics Announce Collaboration
Company has announced collaboration to develop a premium exome that provides a streamlined workflow for 10x Genomics'Chromium platform.
Friday, February 12, 2016
Agilent Wins Award for Innovation in LC
Dual-needle technology enhances speed, flexibility.
Thursday, January 28, 2016
Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
PerkinElmer supplies chips for Agilent's popular 2100 Bioanalyzer system.
Thursday, January 21, 2016
Agilent Signs Agreement with Thermo Fisher Scientific
Agreement to exchange instrument controls to improve the productivity and user experience.
Thursday, November 12, 2015
Agilent Completes Acquisition of Seahorse Bioscience
Agilent has completed the acquisition of Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics.
Tuesday, November 03, 2015
Agilent Recognizes Australian Genome Research Facility as Certified Service Provider
Nonprofit organization offers scientists access to leading-edge technologies.
Saturday, October 31, 2015
Agilent Announces Opening of Life Science Research Center
Facility designed to advance multi-omics research.
Thursday, September 24, 2015
Agilent to Acquire Seahorse Bioscience
Acquisition complements Agilent’s market-leading separations and mass spectrometry solutions, expands pharma offerings.
Thursday, September 10, 2015
Agilent, Singapore Institute Collaborate
Agilent Technologies and Singapore's Bioprocessing Technology Institute today announced a collaboration to develop new analytical approaches to specific protein-linked sugar compounds.
Wednesday, July 15, 2015
Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Agilent Technologies and Waters Corporation Formalize Instrument Control Exchange
Agilent Technologies Inc. and Waters Corp have announced a formal agreement to exchange instrument controls to improve the productivity of customers who own software and instruments from both companies.
Wednesday, July 01, 2015
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!